HC Wainwright Affirms Alkermes (ALKS) 'Neutral' Rating on Vibrance-1 Phase 2 Study

Alkermes (NASDAQ:ALKS) is one of the best beginner stocks to buy, according to analysts. On September 9, HC Wainwright reiterated a ‘Neutral’ rating on the stock and a $46 price target. The stance follows the company’s positive results from the Vibrance-1 phase 2 study.

Study results show that Alixorexton is the first orexin 2 receptor agonist to demonstrate a clinically meaningful and statistically significant impact on wakefulness, cognition, and fatigue. The company is developing Alixorexton as an oral selective orexin treatment for NT1 narcolepsy and idiopathic hypersomnia (IH).

“The improvements in patient-reported outcomes, especially those related to fatigue and cognitive function, suggest that Alixorexton may offer meaningful relief across a spectrum of symptoms that impact patients,” said Giuseppe Plazzi, MD, PhD, a neurologist, and director of the Narcolepsy Center at the IRCCS of the Neurological Sciences of Bologna

The impressive outcomes from Vibrance-1 highlight the potency of the orexin program as Alkermes looks to usher in a new era of neuroscience innovation.

Alkermes Plc. (NASDAQ:ALKS) It is a global biopharmaceutical company that develops and commercializes medicines for complex and difficult-to-treat psychiatric and neurological disorders, including addiction, schizophrenia, and bipolar disorder. The company has a portfolio of marketed products and a pipeline of investigational drug candidates, with a focus on neuroscience.

While we acknowledge the potential of ALKS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Tech Stocks to Buy According to Cathie Wood and 13 Best Tech Stocks to Buy for the Long Term.

Disclosure: None. This article is originally published at Insider Monkey.